Listeria variants and their usage
A mutated Variantlisteria bacterium with adenosine trophism and isoprenoid synthesis capabilities addresses safety and efficacy issues of Listeria monocytogenes vaccines, enhancing cancer immunotherapy by inducing potent cellular immunity while minimizing systemic infection.
Patent Information
- Application Number
- JP2026528922
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-14
- Filing Date
- 2024-11-13
- Publication Date
- 2026-11-19
AI Technical Summary
Existing Listeria monocytogenes strains used as live vaccines for cancer immunotherapy face safety and efficacy concerns, including low immunogenicity and adverse events, limiting their therapeutic potential.
Development of a Variantlisteria bacterium with mutations in the purA gene for adenosine trophism, combined with heterologous nucleic acids for isoprenoid synthesis and additional mutations for aerobic growth, to create a safer and more potent immunogenic agent.
The Variantlisteria bacterium induces robust cellular immunity and reduces systemic infection risks, providing a safer and more effective cancer immunotherapy option.
Smart Images

Figure 2026539107000009 
Figure 2026539107000010 
Figure 2026539107000011
Abstract
Description
[Technical Field]
[0001] cross reference This application claims the benefit of U.S. Provisional Patent Application No. 63 / 598,660, filed on 14 November 2023, which is incorporated herein by reference in its entirety.
[0002] Description of federally funded research. This invention was made with government support under grant numbers AI027655 and AI063302, awarded by the National Institutes of Health. The government has certain rights to this invention.
[0003] Reference to electronically submitted materials The sequence listing is provided herein as a sequence listing XML file, "BERK-492PRV_SEQ_LIST," created on October 24, 2023, and having a size of 7,956 bytes. The contents of the said sequence listing XML are incorporated herein by reference in their entirety. [Background technology]
[0004] Introduction Listeria monocytogenes is a rapidly growing, Gram-positive, facultative intracellular bacterial pathogen in humans and animals. This bacterium is genetically engineerable, and the cellular biology of its infection has been extensively characterized. L. monocytogenes can invade host cells, including specialized antigen-presenting cells (APCs), rapidly escape from phagosomes, and deliver antigens and metabolites that induce robust host cellular immunity (CMI), allowing it to proliferate in the host cytoplasm. In addition, L. monocytogenes does not cause rapid cell death of host APCs, another feature that promotes CMI development. Due to its ability to induce a potent antigen-specific T cell response, L. monocytogenes has been used as a therapeutic vaccine in over 20 cancer clinical trials, administered to over 1800 patients. However, antigen-specific CD8 markers observed in preclinical mouse studies have been negatively impacted. + In contrast to the potent stimulation of cytotoxic T cells, the L. monocytogenes vaccine exhibited low immunogenicity in clinical trials. In rare cases, live bacteria were detected in patients' blood or on implants after administration of the live vaccine. Furthermore, even attenuated vaccine strains still caused serious adverse events, resulting in the discontinuation of clinical trials. [Overview of the Initiative]
[0005] overview Partly due to safety and efficacy concerns regarding the use of L. monocytogenes as a live vector for cancer immunotherapy, the inventors recognized the need for a safer and more potent L. monocytogenes strain. Accordingly, this disclosure provides a Variantlisteria bacterium that is an adenosine trophic adjuvant containing a mutation in the purA gene encoding adenylosuccinate synthase. This disclosure provides a composition comprising the Variantlisteria bacterium of interest, which further comprises a multispecific antibody. Also provided are an immunogenic composition comprising the Variantlisteria bacterium of this disclosure and a kit comprising a unit dose thereof. This disclosure further provides a method for inducing an immune response in an organism, the method comprising administering an effective amount of the immunogenic composition of this disclosure to the organism.
[0006] This disclosure provides a Variantlisteria bacterium that is an adenosine nutrient requirement, comprising a mutation in the purA gene encoding adenylosuccinate synthase. In some cases, the mutation is a deletion of all or part of the purA gene. In some embodiments, the Variantlisteria bacterium does not grow extracellularly in mammals. In some embodiments, the Variantlisteria bacterium requires adenosine supplementation of 100 μM to 500 μM to grow. In certain embodiments, the Variantlisteria bacterium further comprises a deletion of all or part of the endogenous ribC gene and / or the endogenous ribF gene.
[0007] In certain embodiments, the *Variantlisteria* bacterium is genetically modified to contain one or more heterologous nucleic acids. In some cases, one or more heterologous nucleic acids are incorporated into the bacterial genome. In some embodiments, one or more heterologous nucleic acids contain nucleotide sequences encoding polypeptides necessary for isoprenoid synthesis via the non-mevalonate pathway, and the *Variantlisteria* bacterium grows aerobically. In some embodiments, one or more heterologous nucleic acids contain nucleotide sequences encoding IspE, GcpE, and IspA polypeptides. In some embodiments, one or more heterologous nucleic acids contain nucleotide sequences encoding Dxs, IspD, IspF, IspE, GcpE, and IspA polypeptides. In some embodiments, the *Variantlisteria* bacterium in question may further contain loss-of-function mutations in the endogenous LytB gene. In some embodiments, the *Variantlisteria* bacterium further contains one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions. In some cases, one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions include mutations in endogenous genes selected from lmo1694, fur, flgE, ribF, uracil DNA glycosylase, DNA-directed RNA polymerase subunit α, UDP-N-acetylglucosamine 1-carboxyvinyltransferase, and heptaprenyl diphosphate synthase component I. In certain embodiments, at least one of one or more heterologous nucleic acids includes a nucleotide sequence encoding an antigen polypeptide. In some cases, the antigen is a cancer-associated antigen.
[0008] In certain embodiments, a bacterium of the genus Variantlisteria further comprises one or more additional mutations that give the bacterium a reduced phenotype and / or one or more additional mutations that provide a growth advantage. In some cases, the one or more additional mutations that give the reduced phenotype include mutations in a gene selected from the actA gene and the inlB gene, and the one or more additional mutations that provide a growth advantage include mutations in the eetB gene.
[0009] In some aspects, the genus Variantlisteria is Variantlisteria monocytogenes.
[0010] This disclosure provides compositions comprising a target variant of Listeria bacteria. In certain embodiments, the composition further comprises a multispecific antibody comprising a first antigen-binding site specific to a cancer-associated antigen and a second antigen-binding site specific to T cells. In some embodiments, the T cells are mucosa-associated invariant T (MAIT) cells, γ / δ T cells, CD8 + This may be T cells or natural killer (NK) cells. The disclosure further provides immunogenic compositions comprising the target Variantlisteria bacterium.
[0011] This disclosure provides a method for inducing an immune response in an organism, the method comprising administering an effective amount of the immunogenic composition of this disclosure to the organism. In certain embodiments of the method, a Variantlisteria bacterium is genetically modified to contain one or more heterologous nucleic acids comprising a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, the Variantlisteria bacterium grows aerobically, and the immune response is induced to a phosphorylated antigen (phosphoantigen) produced by the Variantlisteria bacterium. In some cases, the phosphorylated antigen is (E)-4-hydroxy-3-methyl-buta-2-enylpyrophosphate (HMBPP). In certain embodiments of the method, the Variantlisteria bacterium is genetically modified to contain a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous polypeptide, and the immune response is induced to the heterologous polypeptide. In some cases, the heterologous polypeptide is an antigen. In some cases, the antigen is a cancer-associated antigen. In some embodiments, the immune response comprises a gamma-delta T cell response.
[0012] This disclosure further provides a kit comprising a unit dose of the immunogenic composition of interest. In certain embodiments, the unit dose is an oral dose. In certain embodiments, the unit dose is injectable. In some embodiments, the kit further comprises a recombinant expression vector comprising a nucleotide sequence encoding a heterologous polypeptide. In some cases, the heterologous polypeptide is an antigen. In some cases, the antigen is a cancer-associated antigen. [Brief explanation of the drawing]
[0013] [Figure 1] Figure 1 shows the growth curve of the ΔpurA mutant in chemically defined media supplemented with the indicated concentrations of adenosine. Bacterial cultures incubated overnight were diluted to an OD600 of 0.05 to initiate the growth curve, and then incubated at 37°C with agitation. Growth was monitored by spectrophotometrics. [Figure 2]Figures 2A-2B show the growth of the ΔpurA mutant in blood and serum. Bacteria in the logarithmic metaphase were inoculated into 3 ml of culture medium at a density of 1 × 10⁶ CFU per ml. Growth was measured by plating on BHI agar after 24 hours of incubation in a 37°C shaker. (Figure 2A) Growth in defibrinized sheep blood. (Figure 2B) Growth in sterile human serum buffered to pH 7.0 with 5 mM HEPES. Three independent experiments were aggregated. Student's t-test, ***P<0.001. [Figure 3] Figures 3A-3B show that the ΔpurA mutant does not proliferate in the cytoplasm of bone marrow-derived macrophages (BMMs). (A) Phagosome escape. BMMs were infected with metaphase logarithmic bacteria at an MOI of 5-10 for 30 minutes in the presence of cytochalasin D, as previously reported. The relative escape rate was measured by comparing the percentage of p62+ bacteria to the total intracellular bacteria with that of wild-type (WT) bacteria. Data are shown as mean ± SD. Three independent experiments were combined, and more than 100 bacteria were analyzed for each strain in each experiment. Student's t-test. *P<0.05. (B) Intracellular growth curve in BMMs. BMMs were infected at an MOI of 0.25 for 30 minutes. Adenosine was added to the BMM medium 1 hour after infection. [Figure 4]Figures 4A to 4C show that the ΔpurA mutant is significantly attenuated in mice. 8-week-old CD-1 mice (Charles River) were infected by intravenous injection of 1×10⁵ CFU of the indicated strain. Bacterial burdens in the liver, spleen (A), and gallbladder (B) were measured 48 hours post-infection by plating homogenized organs. Each circle represents an individual mouse. The line indicates the median. Two biological replicates were pooled, for a total of 6 to 10 mice per strain. P values from unpaired Student's t-test are shown. L.o.d., limit of detection. (C) In vivo growth curves in mice. 8-week-old CD-1 mice (Charles River) were infected by intravenous injection of 1×10⁵ colony forming units (CFU) of the indicated strain. Bacterial burdens in the liver (left) and spleen (right) were measured at 0.5 hours, 5 hours, 10 hours, 24 hours, and 48 hours post-infection. Two biological replicates were pooled, for a total of 7 to 9 mice per strain. L.o.d., limit of detection. [Figure 5] Figures 5A to 5B show that the ΔpurA mutant induces potent cellular immunity. (A) Vaccination with the ΔpurA mutant confers long-term protection against wild-type L. monocytogenes. C57BL / 6J mice were vaccinated by intravenous injection of 10³ or 10⁵ CFU of L. monocytogenes. Four weeks after vaccination, the mice were challenged intravenously with 5×10⁴ CFU of wild-type L. monocytogenes. Three days after challenge, wild-type CFU were enumerated from the spleen. Data were pooled from 3 independent experiments for the 10³ group and 2 experiments for the 10⁵ group. L.o.d., limit of detection. (B) The ΔpurA mutant induced a potent cytotoxic CD8+ T cell response. C57BL / 6J mice were infected by intravenous injection of 10³ CFU of the indicated attenuated strain. Single-cell suspensions of spleen cells were stimulated with an OVA-specific epitope in the presence of a protein transport inhibitor. Antigen-specific CD8+ T cell responses were assessed by intracellular cytokine staining 7 days after a single vaccination. Data were pooled from 3 independent experiments. One-way ANOVA, multiple comparisons; ns, no significant difference; *P < 0.05; ***P < 0.001; ****P < 0.0001. [Mode for Carrying Out the Invention]
[0014] Definitions As used herein, "heterologous" refers to a nucleic acid or polypeptide that is not found in a naturally occurring bacterium (e.g., a Listeria bacterium). For example, a "heterologous" nucleic acid comprising a nucleotide sequence encoding a polypeptide in the non-mevalonate pathway is a nucleic acid that is not found in a naturally occurring bacterium (e.g., a Listeria bacterium). As used herein, "heterologous" also refers to a nucleic acid or polypeptide that is not found in the respective native nucleic acid or polypeptide. For example, a promoter sequence heterologous to a non-mevalonate pathway gene is a promoter sequence that is not naturally found to be associated with the non-mevalonate pathway gene.
[0015] As used herein, the term "naturally occurring" as applied to a nucleic acid, protein, cell, or organism refers to a nucleic acid, cell, protein, or organism that is found in nature.
[0016] The terms "polynucleotide" and "nucleic acid" as used interchangeably herein refer to either ribonucleotides or deoxyribonucleotides, which are polymeric forms of nucleotides of any length. Accordingly, the term includes, but is not limited to: single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids; or polymers comprising purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The terms "polynucleotide" and "nucleic acid" should be understood to include single-stranded (e.g., sense or antisense) and double-stranded polynucleotides, as applicable to the described embodiments.
[0017] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein and refer to polymeric forms of amino acids of any length, which may include genetically encoded and non-genetically encoded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having a modified peptide backbone. The terms include, but are not limited to, fusion proteins having heterologous amino acid sequences; fusions having heterologous and phased leader sequences with or without an N-terminal methionine residue; immunologically tagged proteins, and the like.
[0018] As used herein, the term “isolated” means that a polynucleotide, polypeptide, or cell (e.g., a Listeria bacterium) is in an environment different from the environment in which the polynucleotide, polypeptide, or cell naturally exists. Isolated genetically modified cells may be present in a mixed population of genetically modified cells.
[0019] As used herein, “recombinant” means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and / or ligation steps, resulting in a construct having a structural coding or non-coding sequence distinct from endogenous nucleic acids found in the natural system. Generally, to provide synthetic nucleic acids expressible from recombinant transcription units contained within cells, or expressible in cell-free transcription and translation systems, DNA sequences encoding structural coding sequences can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides. Such sequences may be provided in the form of internal non-coding sequences, i.e., open reading frames not interrupted by introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences can also be used to form recombinant genes or transcription units. The non-coding DNA sequences may be located at 5' or 3' of the open reading frame, and such sequences may not interfere with the manipulation or expression of the coding region, but may actually act to regulate the production of the desired product through various mechanisms (see “DNA Regulatory Sequences” below).
[0020] Therefore, for example, the term “recombinant” polynucleotide or “recombinant” nucleic acid refers to something that does not exist naturally, for example, something created through artificial intervention by combining two other distinct sequence segments. This artificial combination is often achieved either by chemical synthesis or by artificially manipulating isolated nucleic acid segments, such as by genetic engineering techniques. This is typically done to replace a codon with a redundant codon that codes for the same amino acid or a conserved amino acid, while typically introducing or removing a sequence recognition site. Alternatively, nucleic acid segments with desired functions may be joined together to produce a combination of desired functions. This artificial combination is often achieved either by chemical synthesis or by artificially manipulating isolated nucleic acid segments, such as by genetic engineering techniques.
[0021] Similarly, the term "recombinant" polypeptide refers to a polypeptide that does not exist in nature and is created, for example, through artificial intervention by combining two different distinct amino acid sequence segments. Therefore, for example, a polypeptide containing heterologous amino acid sequences is a recombinant.
[0022] "Construction" or "vector" refers to recombinant nucleic acid, commonly recombinant DNA, that is produced for the purpose of expressing and / or increasing a specific nucleotide sequence(s), or that will be used in the construction of other recombinant nucleotide sequences.
[0023] The terms “DNA regulatory sequence,” “regulatory element,” and “regulatory element,” as used interchangeably herein, refer to transcriptional and translational regulatory sequences such as promoters, enhancers, polyadenylation signals, terminators, and proteolytic signals that provide and / or control the expression of coding sequences and / or the production of coded polypeptides in host cells.
[0024] The term “transformation” is used herein interchangeably with “genetic modification” and refers to a permanent or transient genetic change induced in a cell after the introduction of a new nucleic acid (e.g., exogenous DNA to the cell) into the cell. Genetic change ("modification") can be achieved either by the integration of the new nucleic acid into the host cell’s genome or by the transient or stably maintained maintenance of the new nucleic acid as an episomal element. If the cell is a prokaryotic cell, the permanent change can also be introduced into the chromosome or via extrachromosomal elements such as plasmids and expression vectors, which may include one or more selectable markers to aid in their maintenance in recombinant host cells. Appropriate methods of genetic modification include viral infection, transfection, conjugation, protoplast fusion, electroporation, and calcium phosphate precipitation. A general description of these methods can be found in Ausubel, et al., Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995.
[0025] "Functionally linked" refers to a juxtaposition of components described in this way that is related in a way that enables them to function in the way they are intended. For example, if a promoter affects its transcription or expression, the promoter is functionally linked to the coding sequence. As used herein, the terms "heterogeneous promoter" and "heterogeneous regulatory region" refer to promoters and other regulatory regions that are not typically associated with a particular nucleic acid in nature. For example, a "heterogeneous transcriptional regulatory region relative to a coding region" is a transcriptional regulatory region that is not typically associated with a coding region in nature.
[0026] One polynucleotide or polypeptide has a certain percentage of "sequence identity" with another polynucleotide or polypeptide, meaning that when aligned, the two sequences will have the same percentage of bases or amino acids and will be in the same relative positions. Sequence similarity can be determined in several different ways. To determine sequence identity, sequences can be aligned using methods and computer programs, including BLAST, which is available on the World Wide Web at ncbi.nlm.nih.gov / BLAST. See, for example, Altschul et al. (1990), J. Mol. Biol. 215:403-10. Another alignment algorithm is FASTA, available in the Genetics Computing Group (GCG) package, a wholly owned subsidiary of Oxford Molecular Group, Inc., located in Madison, Wisconsin, USA. Other alignment techniques are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Of particular interest are alignment programs that allow gaps in sequences. Smith-Waterman is one type of algorithm that allows gaps in sequence alignment. See Meth. Mol. Biol. 70:173-187 (1997). Also, a GAP program using the Needleman and Wunsch alignment method can be used for sequence alignment. See J. Mol. Biol. 48:443-453 (1970).
[0027] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described and is therefore naturally subject to change. Since the scope of the present invention is limited only by the appended claims, it should also be understood that the terms used herein are intended to describe only specific embodiments and are not intended to limit them.
[0028] Where a range of values is provided, unless the context clearly indicates otherwise, it should be understood that the upper and lower limits of that range, and each intermediary value between any other stated values or intermediary values within that stated range, are included in the invention up to one-tenth of the unit of its lower limit. The upper and lower limits of these smaller ranges may independently be included in smaller ranges, provided that they have any specifically excluded limitations within the stated range, and are also included in the invention. Where a stated range includes one or both of the upper and lower limits, ranges excluding either or both of those included upper and lower limits are also included in the invention.
[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which the present invention pertains. Any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention, but preferred methods and materials are described herein. All publications referenced herein are incorporated herein by reference, disclosing and describing methods and / or materials in relation to those publications cited herein.
[0030] It should be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” refer to multiple subjects unless the context clearly indicates otherwise. For example, a reference to “Variantlisteria bacteria” includes multiple such bacteria, and a reference to “mutations in the purA gene” includes one or more mutations in the purA gene and their equivalents known to those skilled in the art, and so on. Furthermore, it should be noted that claims may be drafted to exclude any particular element. Therefore, this statement is intended to serve as an antecedent for the use of exclusive terms such as “only,” “solely,” or for the use of “negative” limitation in connection with the enumeration of claim elements.
[0031] In the context describing this disclosure (particularly in the context of the following claims), the terms “a,” “an,” and “the,” as well as similar reference terms, are to be interpreted as covering both singular and plural forms unless otherwise specifically indicated herein or unless the context clearly contradicts them. The terms “comprising,” “having,” “including,” and “containing” are to be interpreted as open-ended terms (i.e., “including but not limited to”) unless otherwise specifically indicated herein. Enumerations of value ranges herein are intended simply as abbreviations to refer individually to each distinct value that falls within the range unless otherwise specifically indicated herein, and each distinct value is incorporated herein as if it were individually enumerated herein. For example, if the range 10–15 is disclosed, then 11, 12, 13, and 14 are also disclosed. All methods described herein may be performed in any suitable order unless otherwise specifically indicated herein or unless the context clearly contradicts them. Any and all examples or illustrative phrases provided herein (e.g., "etc.") are used solely to better illustrate aspects of the disclosure and, unless otherwise claimed, do not limit the scope of the disclosure.
[0032] As used herein, the term "about" in relation to quantity indicates that the quantity may vary by 10% from the stated quantity. For example, "about 100" means a quantity between 90 and 110. When "about" is used in the context of a range, "about" used in relation to a lower quantity within a range means that the lower quantity includes a quantity 10% lower than the lower quantity within that range, and "about" used in relation to a higher quantity within a range means that the higher quantity includes a quantity 10% higher than the higher quantity within that range. For example, "about 100 to about 1000" means that the range extends from 90 to 1100.
[0033] As used herein, terms such as “and / or” and “A and / or B” are intended to include both A and B; A or B; A (alone); and B (alone). Similarly, as used herein, terms such as “and / or” and “A, B, and / or C” are intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0034] The aspects and aspects of the disclosure described herein are understood to include the aspects and aspects of "comprising," "consisting," and "consisting essentially of."
[0035] For clarity, certain features of the Invention described in the context of a separate embodiment may also be provided in combination in a single embodiment. Conversely, various features of the Invention described in the context of a single embodiment may also be provided individually or in any suitable subcombination. All combinations of embodiments relating to the Invention are specifically encompassed in the Invention and are disclosed herein as if every possible combination were individually and expressly disclosed. In addition, all subcombinations of various embodiments and their elements are also specifically encompassed in the Invention and are disclosed herein as if every possible subcombination were individually and expressly disclosed herein.
[0036] The publications discussed herein are provided only for disclosures prior to the filing date of this application. Nothing in this specification should be construed as an acknowledgment that the present invention has no prior rights to such publications due to prior art. Furthermore, the publication dates presented may differ from the actual publication dates, which may need to be verified on a case-by-case basis.
[0037] Detailed explanation This disclosure provides a Variantlisteria bacterium that is an adenosine trophic addict and contains a mutation in the purA gene encoding adenylosuccinate synthase. This disclosure provides a composition comprising the Variantlisteria bacterium of interest, which further comprises a multispecific antibody. Also provided are an immunogenic composition comprising the Variantlisteria bacterium of this disclosure and a kit comprising a unit dose thereof. This disclosure further provides a method for inducing an immune response in an organism, the method comprising administering an effective amount of the immunogenic composition of this disclosure to the organism.
[0038] Bacteria of the genus Variantlisteria De novo synthesis and / or acquisition of purine and pyrimidine nucleotides are necessary for various bacterial cellular functions such as energy storage, second messenger signaling, and genome replication, and are therefore essential for proliferation. However, the average concentrations of purine bases and nucleosides (e.g., adenosine, guanosine) in extracellular fluid are low (e.g., in the range of 0.4–6 μM). Therefore, de novo nucleotide biosynthesis is a crucial metabolic function necessary for bacterial growth in the extracellular environment (e.g., blood). Facultative intracellular pathogens such as L. monocytogenes can survive and proliferate in the extracellular environment during systemic infection, limiting their therapeutic potential. Examples of extracellular proliferation niches for Listeria bacteria (e.g., L. monocytogenes) include blood and the gallbladder. Notably, adenosine is abundant in the tumor microenvironment. Therefore, engineered adenosine trophicers of Listeria bacteria would lose their ability to grow well in adenosine-poor extracellular niches and would prove advantageous for therapeutic use (e.g., cancer immunotherapy). For example, engineered adenosine trophicers of Listeria bacteria may be useful for inducing CMI in the adenosine-rich tumor microenvironment, while they may not be able to induce systemic infection due to the low availability of adenosine in other extracellular niches.
[0039] Accordingly, this disclosure provides a Variantlisteria bacterium that contains a mutation in the purA gene encoding adenylosuccinate synthase and is an adenosine nutrient requirement bacterium.
[0040] Adenylosuccinate synthase, coupled with the hydrolysis of GTP, catalyzes the conversion of inosine monophosphate (IMP) and L-aspartate to adenylosuccinate. The reaction catalyzed by adenylosuccinate synthase is the first commit step in the de novo synthesis of the purine nucleotide adenosine monophosphate (AMP) and plays a crucial role in regulating purine nucleotide interconversion. Appropriate mutations in the purA gene may include any mutation that disrupts the activity of adenylosuccinate synthase encoded by the purA gene, making the target Listeria bacterium an adenosine trophicer. Examples of appropriate mutations include, but are not limited to, missense mutations, in-frame deletions, in-frame insertions, out-of-frame deletions, out-of-frame insertions, and early stop codons. In some cases, the target mutation is an in-frame deletion. In some cases, the target mutation is a deletion of all or part of the purA gene. In some cases, the target mutation is a complete deletion of the purA gene. In some cases, the target mutation is a partial deletion of the purA gene. In some cases, the target mutation is an in-frame deletion within the purA gene. In some embodiments, the mutation is not a transposon insertion (i.e., the target Listeria bacterium does not contain a transposon insertion that would make it an adenosine trophicer by disrupting the purA gene).
[0041] "Adenosine nutrient requirement" means that a target Listeria species requires additional adenosine supplementation to grow and / or proliferate compared to wild-type Listeria. Adenosine nutrient requirement can be assessed by measuring the growth and / or proliferation rates of the target Listeria species in chemically defined media with various levels of supplemented adenosine, compared to wild-type Listeria (e.g., in a chemically defined medium supplemented with 0 μM adenosine, and in a chemically defined medium supplemented with 100 μM adenosine). For example, if wild-type Listeria exhibits a certain growth rate in a chemically defined medium without adenosine, an adenosine nutrient requirement Listeria species may not be able to grow in a chemically defined medium without adenosine and may only exhibit a comparable growth rate in a chemically defined medium supplemented with 100 μM adenosine. Methods for measuring the growth rate of bacterial cultures (for example, measuring the optical density of a liquid culture inoculated with the bacteria) are well known in the art.
[0042] In certain embodiments, the Variantlisteria species of this disclosure require 100 μM to 500 μM of adenosine supplementation to grow, for example, in some cases, Variantlisteria bacteria require 100 μM to 150 μM of adenosine supplementation, 150 μM to 200 μM of adenosine supplementation, 250 μM to 300 μM of adenosine supplementation, 300 μM to 350 μM of adenosine supplementation, 350 μM to 400 μM of adenosine supplementation, 400 μM to 450 μM of adenosine supplementation, and 450 μM to 500 μM of adenosine supplementation. Wild-type Listeria bacteria may not require adenosine supplementation to grow, for example (for example, in some cases, wild-type Listeria may not require exogenous adenosine to grow). In some embodiments, the target *Listeria* bacteria can be grown (cultured) in vitro in adenosine-supplemented culture medium, but do not grow extracellularly in vivo. In some cases, the target *Listeria* bacteria do not grow extracellularly in vivo in mammals. In some embodiments, the *Listeria* bacteria of this disclosure require adenosine supplementation for growth and are therefore conditionally obligate intracellular bacteria in vivo (e.g., in mammalian or other animal hosts). In some embodiments, the target *Listeria* bacteria of this disclosure can survive within tumors (e.g., the target *Listeria* bacteria can survive extracellularly in the tumor microenvironment).
[0043] In some embodiments, the Variantlisteria bacteria of this disclosure further include mutations in the ribC gene and / or the ribF gene. In some cases, the mutations include deletions of all or part of the ribC gene and / or the ribF gene. The ribC and ribF genes are required for the biosynthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). RibC is a bifunctional enzyme that catalyzes the phosphorylation of riboflavin to FMN and the adenylylation of FMN to form FAD. RibF also converts FMN to FAD by adenylylation. In some embodiments, the Variantlisteria bacteria of this disclosure, including mutations in the ribC gene and / or the ribF gene, can be grown (cultured) in vitro in culture media supplemented with FMN and FAD, but cannot grow extracellularly in vivo (e.g., in the body of a mammal). In some embodiments, the variant Listeria species of the present disclosure, comprising mutations in the ribC gene and / or ribF gene, require supplementation of flavin mononucleotides and flavin adenine dinucleotides to grow and are therefore conditionally obligate intracellular bacteria in vivo (e.g., in a mammalian or other animal host).
[0044] The variant Listeria bacteria of this disclosure may include, in addition to the ribC / ribF modification described above, a deletion of all or part of the eetB gene. Deleting all or part of the eetB gene can provide a growth advantage. In some cases, such variant strains exhibit an increased growth rate in in vitro broth compared to the growth rate in broth of Listeria bacteria containing the ribC / ribF modification but without the eetB gene deletion.
[0045] In certain embodiments, the target *Listeria* bacteria are genetically modified to contain one or more heterologous nucleic acids. In some embodiments, the one or more heterologous nucleic acids contain nucleotide sequences encoding polypeptides necessary for isoprenoid synthesis via the non-mevalonate pathway, and the *Listeria* bacteria grow aerobically. The mevalonate pathway for isoprenoid biosynthesis is an essential metabolic pathway for isoprenoid biosynthesis in eukaryotes, archaea, and some bacteria. The non-mevalonate pathway is an alternative metabolic pathway for isoprenoid synthesis, specific to bacteria and some parasites. Strictly controlled expression of non-mevalonate pathway genes (e.g., by separating them into operons under the control of a single promoter) is necessary to avoid toxicity due to the accumulation of intermediate products. While most organisms encode either the mevalonate or non-mevalonate pathway for isoprenoid biosynthesis, *Listeria* is among the very few bacteria that encode both pathways. Enzymes in the non-mevalonate pathway include the proteins Dxs, IspD, IspF, LytB, IspE, GcpE, and IspA. Dxs catalyzes the conversion of pyruvate and D-glyceraldehyde 3-phosphate to 1-deoxy-D-xylulose 5-phosphate (DOXP). IspD catalyzes the conversion of 2-C-methyl-D-erythritol 4-phosphate (MEP) to 4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME). IspF catalyzes the conversion of 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (CDP-MEP) to 2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MEcPP). LytB (i.e., IspH) catalyzes the conversion of (E)-4-hydroxy-3-methyl-buta-2-enyl pyrophosphate (HMBPP) to dimethylallyl pyrophosphate (DMAPP). IspE catalyzes the conversion of 4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME) to 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (CDP-MEP).GcpE catalyzes the conversion of 2-C-methyl-D-erythritol-2,4-cyclodiphosphate (MEcPP) to (E)-4-hydroxy-3-methylbuta-2-enylpyrophosphate (HMBPP). IspA catalyzes the conversion of dimethylallyl pyrophosphate (DMAPP) to farnesyl pyrophosphate (FPP). However, in Listeria bacteria, the undenatured non-mevalonate pathway can only be used anaerobically; therefore, isoprenoid production via the undenatured non-mevalonate pathway is limited to anaerobic conditions.
[0046] In some embodiments of the target Variantlisteria bacteria, all polypeptides required for isoprenoid synthesis via the non-mevalonate pathway are encoded on a single heteronucleotide, and the nucleotide sequence encoding all polypeptides is functionally linked to a single transcriptional regulatory element (e.g., a single promoter). In some cases, all polypeptides required for isoprenoid synthesis via the non-mevalonate pathway are encoded on separate heteronucleotides. In some embodiments, one or more heteronucleotides include nucleotide sequences encoding IspE, GcpE, and IspA polypeptides. In some embodiments, one or more heteronucleotides include nucleotide sequences encoding Dxs, IspD, IspF, IspE, GcpE, and IspA polypeptides.
[0047] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding a Dxs polypeptide that have 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000001.tif69160.
[0048] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding an IspD polypeptide with 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000002.tif23158.
[0049] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding an IspF polypeptide with 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000003.tif17157.
[0050] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding an IspE polypeptide that have 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000004.tif30159.
[0051] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding a GcpE polypeptide that have 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000005.tif43159.
[0052] In some embodiments, heterologous nucleic acids have the following amino acid sequence: It may contain nucleotide sequences encoding an IspA polypeptide with 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with TIFF2026539107000006.tif30160.
[0053] In some cases, one or more heterologous nucleic acids include a nucleotide sequence encoding a polypeptide containing an amino acid sequence having 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with respect to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. In some cases, one or more heterologous nucleic acids include a nucleotide sequence encoding a polypeptide containing an amino acid sequence having 80% or more (e.g., at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) amino acid sequence identity with respect to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
[0054] In some embodiments, the bacterium of the genus Variantlisteria further includes mutations in the endogenous LytB gene such that the endogenous LytB gene becomes non-functional, in addition to one or more heteronucleotides containing, for example, a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via the non-mevalonate pathway. In some cases, the mutation in the endogenous LytB gene is the deletion of all or part of the endogenous LytB gene. As described above, the LytB (i.e., IspH) enzyme encoded by the LytB gene catalyzes the conversion of (E)-4-hydroxy-3-methyl-buta-2-enylpyrophosphate (HMBPP) to dimethylallylpyrophosphate (DMAPP) in the non-mevalonate pathway of isoprenoid synthesis. Therefore, a target variant of Listeria containing a mutation in the endogenous LytB gene that renders the endogenous LytB gene nonfunctional can be used when increased HMBPP production by the target Listeria bacterium is desired.
[0055] Whereever heteronucleotides are referred to in relation to the Variantlisteria species covered throughout this disclosure (see, for example, the preceding paragraph), heteronucleotides may also be called exogenous nucleic acids. Accordingly, any disclosure relating to “heteronucleotides,” or Variantlisteria species genetically modified to contain one or more heteronucleotides, may be considered a disclosure relating to exogenous nucleic acids, or Variantlisteria species genetically modified to contain one or more exogenous nucleic acids. Accordingly, for example, the Variantlisteria species covered may be genetically modified to contain one or more exogenous nucleic acids.
[0056] Mutations in additional genes may enhance the function of the non-mevalonate pathway under aerobic conditions in the target Listeria species. For example, a loss-of-function mutation in fur, which encodes a trivalent iron uptake protein, may improve the aerobic function of the non-mevalonate pathway. In some embodiments, the variant Listeria species of this disclosure may include a loss-of-function mutation in the fur gene. In some embodiments, the variant Listeria species of this disclosure may include a loss-of-function mutation in the lmo1694 gene. In some embodiments, the variant Listeria species of this disclosure may include loss-of-function mutations in the lmo1694 gene and the fur gene. In some cases, the loss-of-function mutations include a frameshift in the lmo1694 gene and a frameshift mutation or termination in the fur gene. In some cases, the loss-of-function mutations include deletions of all or part of the lmo1694 gene and / or the fur gene. In some embodiments, the Variantlisteria bacteria of this disclosure may include mutations in any one of the following genes: flgE, ribF, uracil-DNA glycosylase, DNA-directed RNA polymerase subunit α, UDP-N-acetylglucosamine 1-carboxyvinyltransferase, and heptaprenyl diphosphate synthase component I. Additional embodiments of the Variantlisteria bacteria may include any combination of mutations that enhance the function of the non-mevalonate pathway under the aerobic conditions described above.
[0057] In some embodiments, nucleotide sequences encoding polypeptides of the non-mevalonate pathway are functionally linked to appropriate promoters to enhance the expression of nucleic acids containing the nucleotide sequence and the production of the polypeptide. For example, L. monocytogenes promoter / regulatory sequences that can be used to direct the expression of nucleic acids containing nucleotide sequences encoding polypeptides of the non-mevalonate pathway include, but are not limited to, the promoter sequence of the plcA gene encoding PI-PLC, the promoter sequence of the Listeria mpl gene encoding a metalloproteinase, and the promoter sequence of the Listeria inlA gene encoding internarin, a Listeria membrane protein. Heterogeneous regulatory elements, such as phage-derived promoters and promoters or signal sequences from other bacterial species, may be used for heterogeneous operon expression by Listeria species. Another appropriate promoter is the constitutive HyPer promoter; see, for example, Reniere et al. (2016) PLoS Pathogens doi.org / 10.1371 / journal.ppat.1005741.
[0058] In some embodiments, at least one of one or more heterologous nucleic acids includes a nucleotide sequence encoding an antigen. In certain embodiments, the heterologous antigen can provide protection to the host organism against administration by an infectious agent from which the heterologous antigen originates, or can influence tumor growth and metastasis in a manner beneficial to the host organism. Therefore, heterologous antigens include those identified by infectious agents, where an immune response directed towards the antigen plays a role in preventing or treating the disease caused by the agent. Such heterologous antigens include, but are not limited to, surface proteins of viruses, bacteria, fungi, or parasites, and any other proteins, glycoproteins, lipoproteins, glycolipids, etc. Heterologous antigens include cancer-associated antigens (e.g., tumor antigens). Heterologous antigens also include those that benefit a host organism at risk of developing, or diagnosed with, a tumor expressing the heterologous antigen. The host organism may be a mammal, such as a human.
[0059] As used herein, the terms “antigen” or “heteroantigen” mean a protein or peptide, glycoprotein or glycopeptide, lipoprotein or lipopeptide, or any other macromolecule not normally expressed in Listeria, substantially corresponding to the same antigen in infectious agents, cancer cells, tumor cells, or tumor-associated proteins. Heteroantigens are expressed by the variant Listeria bacteria described herein, processed after infection of a host organism (e.g., a mammal) by the bacteria, and presented to cytotoxic T cells. Heteroantigens expressed by the variant Listeria bacteria do not need to be exactly the same as the corresponding unmodified antigen or protein in tumor cells or infectious agents, as long as they result in a T cell response that recognizes the unmodified antigen or protein naturally expressed in mammals. In other examples, tumor cell antigens may be variants of antigens naturally expressed in a host organism (e.g., a mammal), and the antigen expressed by the variant Listeria bacteria corresponds to that tumor cell variant antigen. As used herein, the terms “tumor-associated antigen” or “cancer-associated antigen” mean an antigen that affects tumor growth or metastasis in a host organism. Tumor-associated antigens may be antigens expressed by tumor cells, or they may be expressed by non-tumor cells but, when expressed in this way, promote the growth or metastasis of tumor cells. The types of tumor antigens and tumor-associated antigens that can be introduced into Listeria by incorporating DNA encoding tumor antigens and tumor-associated antigens include all known and previously unknown tumor antigens. In other examples, "tumor-associated antigens" or "cancer-associated antigens" are used as components of the Listeria vaccine because they do not affect tumor growth or metastasis, but are specifically expressed in the tissue (and tumor) from which the tumor originates. In yet another example, "tumor-associated antigens" or "cancer-associated antigens" are used as components of the Listeria vaccine because they do not affect tumor growth or metastasis, but are selectively expressed in tumor cells and not expressed in any other normal tissue.
[0060] Useful heterologous antigens in vaccine development may be selected using knowledge available to those skilled in the art, and many antigenic proteins are currently known that are expressed by tumor cells, affect tumor growth or metastasis, or are expressed by infectious agents. For example, viral antigens that may be considered useful as heterologous antigens include, but are not limited to, the nucleoprotein (NP) of the influenza virus and the gag protein of the human immunodeficiency virus (HIV). Other heterologous antigens include, but are not limited to, the env protein or its components gp120 and gp41 of HIV, the nef protein of HIV, and the pol protein, reverse transcriptase, and protease of HIV. Further other heterologous antigens may include, but are not limited to, those associated with the hepatitis C virus (HCV), including the E1 and E2 glycoproteins, and non-structural (NS) proteins, such as NS3. In addition, other viral antigens, such as herpesvirus proteins, may also be useful. Heterologous antigens do not need to be of viral origin. Parasitic antigens, such as malaria antigens, are also included, as are fungal antigens, bacterial antigens, and tumor antigens.
[0061] As described herein, several proteins expressed by tumor cells are also known and are of interest as heterologous antigens that can be inserted into the vaccine strains of the present invention. These include, but are not limited to, the bcr / abl antigen in leukemia, the human papillomavirus (HPV) E6 and E7 antigens of oncogenic viruses associated with cervical cancer, the MAGE1 and MZ2-E antigens in or associated with melanoma, and the MVC-1 and HER-2 antigens in or associated with breast cancer. Appropriate heterogeneous antigens include cancer-related antigens such as carcinoembryonic antigen (CEA), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), folate-binding protein (FBP), fetal acetylcholine receptor, ganglioside antigen GD2, Her2 / neu, IL-13R-a2, kappa light chain, LeY, L1 cell adhesion molecule, melanoma-related antigen (MAGE), MAGE-A1, mesothelin, MUC1, NKG2D ligand, carcinoembryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), tumor-related glycoprotein-72 (TAG-72), vascular endothelial growth factor receptor-2 (VEGF-R2), and epidermal growth factor receptor (EGFR) vIII polypeptide. Other coding sequences of interest include, but are not limited to, costimulatory molecules and immunoregulatory molecules.
[0062] As will be understood by those skilled in the art who are given this disclosure, several approaches can be used to express heterologous antigens in Listeria species. In certain embodiments, the gene encoding the heterologous antigen is designed either to enhance the secretion of the heterologous antigen from the bacterium or to enhance the expression of the heterologous antigen on the surface of the Listeria cell. In certain embodiments, a fusion protein is used that contains the desired heterologous antigen and a secreted or cell-surface protein of Listeria. Suitable Listeria proteins that are components of such a fusion protein include, but are not limited to, Listeriolisin O (LLO) and phosphatidylinositol-specific phospholipase (PI-PLC). The fusion protein can be produced by ligating the genes encoding each of the components of the desired fusion protein such that both genes are in frame with each other. Thus, the expression of the ligated gene results in a protein containing both the heterologous antigen and the Listeria protein. The expression of the ligated gene may be placed under transcriptional regulation of a Listeria promoter / regulatory sequence so that the expression of the gene is triggered during the growth and replication of the organism. Signal sequences for the cell surface expression and / or secretion of fusion proteins can also be added to genes encoding heterologous antigens to induce the cell surface expression and / or secretion of the fusion protein. When heterologous antigens are used alone (i.e., without the fused Listeria sequence), it may be advantageous to fuse a signal sequence to them for the cell surface expression and / or secretion of the heterologous antigen. Procedures for achieving this are well known in the arts of bacteriology and molecular biology.
[0063] In some cases, the Listeria species covered by this disclosure are attenuated. “Attenuated” and “attenuated” include Listeria species that have been modified to reduce virulence. The host may be a human or animal host, or an organ, tissue, or cell. In non-limiting examples, Listeria species may be attenuated to reduce binding to host cells (e.g., human or non-human animal cells, e.g., human or non-human mammalian cells), to reduce transmission from one host cell to another, to reduce extracellular growth, or to reduce intracellular growth in a host cell. Attenuation can be assessed, for example, by measuring one or more signs of virulence, LD50, clearance rate from an organ, or competitive index (see, e.g., Auerbuch, et al. (2001) Infect. Immunity 69:5953–5957). Generally, attenuation results in an increase in LD50 (50% lethal dose; the dose (number of bacteria) required to kill half of the members of the tested population after a specific test period) and / or an increase in clearance rate of at least 25%, more commonly at least 50%, most commonly at least 100% (2x), usually at least 5x, more commonly at least 10x, most commonly at least 50x, often at least 100x, more often at least 500x, most commonly at least 1000x, typically at least 5000x, more commonly at least 1000x, more commonly at least 10,000x, most commonly at least 50,000x, and most commonly at least 100,000x. Attenuation can also be assessed by measuring the number of colony-forming units (CFUs).
[0064] In certain embodiments, the attenuated Listeria bacteria according to this disclosure exhibit reduced virulence compared to the corresponding wild-type strain in a competitive index assay described in Auerbach et al., "Development of a Competitive Index Assay To Evaluate the Virulence of Listeria monocytogenes actA Mutants during Primary and Secondary Infection of Mice," Infection and Immunity, September 2001, pp. 5953-5957, Vol. 69, No. 9. In this assay, mice are inoculated with a test strain and a reference strain, e.g., a wild-type bacterial strain. After a period of time, e.g., 48–60 hours, the inoculated mice are sacrificed and the bacterial abundance in one or more organs, e.g., the liver, spleen, etc., is evaluated. In these embodiments, a given bacterial strain is considered less virulent if its abundance in the spleen is at least about 50 times less, e.g., 70 times less, than the abundance observed in the corresponding wild-type strain, and / or if its abundance in the liver is at least about 10 times less or more, e.g., 20 times less, than the abundance observed in the corresponding wild-type strain.
[0065] In further embodiments, bacteria are considered less virulent if they show replication failure in less than 6 hours, including less than 4 hours, as measured using the assay described in Jones and Portnoy, Intracellular growth of bacteria. (1994b) Methods Enzymol. 236:463-467. In further embodiments, bacteria are considered attenuated or less virulent if they form smaller plaques compared to wild-type bacteria in the plaque formation assay used in U.S. Patent No. 7,794,728 (the disclosure of which is incorporated herein by reference), in which cells, e.g., mouse L2 cells, are grown to confluence in, e.g., a 6-well tissue culture dish, and then infected with bacteria. Subsequently, DME agar containing gentamicin is added, and plaques are grown for a period, e.g., 3 days. Then, the cells are incubated overnight to visualize the viable cells by adding an additional DME agar overlay, e.g., neutral red (GIBCO BRL). In such assays, the degree of plaque size reduction observed in attenuated mutants compared to the wild type ranges from 10% to 15%, or even 25% or more, in certain embodiments.
[0066] Attenuated bacteria may contain one or more different mutations that confer an attenuated phenotype, and the mutations of interest may include, for example, hly mutations and / or lplA mutations, as described in U.S. Patent No. 7,794,728 (the disclosure of which is incorporated herein by reference), and actA mutations and / or internalin B (InlB) mutations, as reported in, for example, Dung et al., Clin. Cancer Res. (2012) 18:858-868. Accordingly, in some embodiments, the variant Listeria bacteria of this disclosure may further include mutations in the actA gene and / or inlB gene. In some cases, the mutations include deletions of all or part of the actA gene and / or inlB gene.
[0067] The Variantlisteria bacteria of this disclosure may include one or more genetic modifications in addition to those described above, the one or more additional modifications providing desirable properties in host cells, such as attenuation or enhanced immunogenicity. Examples of such additional modifications include, but are not limited to, those described in PCT publication applications WO 2014 / 106123, WO 2014 / 074635, WO 2009 / 143085, WO 2008027560, WO 2008066774, WO 2007117371, WO 2007103225, WO 2005071088, WO 2003102168, WO 2003 / 092600, WO / 2000 / 009733, and WO 1999 / 025376. The disclosures of these applications are incorporated herein by reference. The variants of the genus *L.* *Monocytogenes-recombinase* (L. monocytogenes-recombinase-induced intracellular death) mutations described herein may include, in addition to the modifications described above. See, for example, USPN 9,511,129.
[0068] Additional embodiments of the Variantlisteria bacteria of this disclosure may include any combination of the above-described mutations / modifications.
[0069] The variant Listeria bacteria described herein can be generated using a variety of different protocols. Therefore, the generation of the target Listeria bacteria can be achieved by many methods well known to those skilled in the art, including mutagenesis resulting from deletion mutagenesis, insertion mutagenesis, point mutations, frameshift mutations, mutations resulting in premature termination of proteins, and mutations in regulatory sequences affecting gene expression. Mutagenesis can be achieved using recombinant DNA technology or conventional mutagenesis techniques, such as selecting mutants after using mutagenic chemicals or radiation. Representative protocols for various methods of generating the bacteria according to the present invention are provided in the experimental sections below.
[0070] Variantlisteria bacteria genetically modified to further contain one or more heterologous nucleic acids described herein can be prepared using a variety of different protocols. The introduction of one or more heterologous nucleic acids into Variantlisteria bacteria can be achieved, for example, by creating recombinant Variantlisteria bacteria in which one or more heterologous nucleic acids are contained in a vector, e.g., a plasmid, which is then maintained and expressed within the Variantlisteria bacteria, and the expression of the heterologous nucleotide sequence is under the control of a prokaryotic promoter / regulatory sequence. Alternatively, one or more heterologous nucleic acids can be stably incorporated into the Variantlisteria bacterial chromosome (i.e., bacterial genome) by, for example, transposon mutagenesis, homologous recombination, or integrase-mediated site-specific integration (described in USSN 10 / 136,860, the disclosure of which is incorporated herein by reference).
[0071] The Listeria cells used to generate the variant Listeria bacteria of this disclosure (e.g., parent Listeria cells) may be any one of several different Listeria species. The Listeria species of interest include, but are not limited to, L. fleischmannii, L. innocua, L. ivanovii, L. marthii, L. monocytogenes, L. rocourtiae, L. seeligeri, L. weihenstephanensis, and L. welshimeri. Therefore, Listeria strains other than L. monocytogenes may also be parent Listeria cells of this disclosure. In certain cases, the Listeria strain is L. monocytogenes.
[0072] Compositions and kits This disclosure provides compositions comprising a target bacterium of the genus Variantlisteria. This disclosure provides compositions comprising (a) a target bacterium of the genus Variantlisteria and (b) a multispecific antibody. The multispecific antibody is optionally a bispecific T cell-inducing (BiTE) antibody. The multispecific antibody has a first antigen-binding site specific to a cancer-associated antigen and a T cell (e.g., mucosa-associated invariant T (MAIT) cells, γ / δ T cells, CD8) + It may include a second antigen-binding site specific to cytotoxic T cells (natural killer (NK) cells). In some embodiments, the T cells are γ / δ T cells. In addition to the Variantlisteria bacteria and multispecific antibodies, the compositions of the present disclosure may include one or more of the following: salts (e.g., NaCl, MgCl2, KCl, MgSO4, etc.), buffers, etc. In some cases, the compositions of the present disclosure may include physiological saline in addition to the Variantlisteria bacteria and multispecific antibodies of the present disclosure.
[0073] This disclosure also provides immunogenic compositions (also referred to herein as “vaccine compositions”) containing the Variantlisteria bacterium of this disclosure. In some embodiments, the immunogenic compositions of this disclosure may include (a) the Variantlisteria bacterium of interest and (b) an antigen or nucleic acid encoding it. Suitable antigens include, but are not limited to, cancer-related antigens and pathogen-related antigens (e.g., viral antigens, pathogenic protozoan antigens). In certain embodiments, the immunogenic composition of interest may further include pharmaceutically acceptable diluents or excipients. Suitable diluents include, for example, sterile distilled water, saline solution, and phosphate buffer. Suitable excipients are also well known to those skilled in the art and can be selected, for example, from A. Wade and PJ Weller, eds., Handbook of Pharmaceutical Excipients (1994) The Pharmaceutical Press: London.
[0074] The present disclosure further provides a kit comprising a unit dose of the subject immunogenic composition comprising the variant Listeria bacterium of the present disclosure. The unit dose of variant Listeria can be 10 per dose 4 ~10 10 bacteria. For example, in some cases, an "effective amount" of the variant Listeria of the present disclosure (a variant Listeria bacterium comprising a mutation in the purA gene encoding adenylosuccinate synthase, which is an adenosine auxotroph) can be, per unit dose, 10 4 ~5×10 4 , 5×10 4 ~10 5 , 10 5 ~5×10 5 , 5×10 5 ~10 6 , 10 6 ~5×10 6 , 5×10 6 ~10 7 , 10 7 ~5×10 7 , 5×10 7 ~10 8 , 10 8 ~10 9 , or 10 9 ~10 10 bacteria. In some embodiments, the unit dose is an oral dose. The oral dose of the subject kit can be in any suitable form. Examples of suitable oral dosage forms include, but are not limited to, capsules, liquid solutions, suspensions, and elixirs. In some embodiments, the unit dose is injectable. The injectable dose of the subject kit can be in any suitable form (e.g., a sterile liquid for formulation).
[0075] In certain embodiments, the subject kits of the present disclosure further comprise a recombinant expression vector (e.g., a plasmid) comprising a nucleotide sequence encoding a heterologous polypeptide. In some embodiments, the heterologous peptide is an antigen. Suitable antigens include, but are not limited to, cancer-associated antigens, pathogen-associated antigens (e.g., viral antigens, pathogenic protozoan antigens, etc.). In some cases, the antigen is a cancer-associated antigen.
[0076] Methods for inducing an immune response This disclosure provides a method for inducing an immune response in an individual, the method comprising administering to the individual an effective amount of a target immunogenic composition (i.e., a “vaccine composition”).
[0077] The target bacteria (Variantlisteria species containing a mutation in the purA gene encoding adenylosuccinate synthase, and being an adenosine trophicer, are used as a vaccine (also referred to herein as “immunogenic composition”). The vaccines of this disclosure are administered to vertebrates by contacting them with a sublethal dose of attenuated Listeria vaccine, the contact typically involving the administration of the vaccine to a host. In some embodiments, the bacteria are provided in a pharmaceutically acceptable formulation. Administration can be oral, parenteral, intranasal, intramuscular, intradermal, intraperitoneal, intravascular, subcutaneous, direct lymph node vaccination, catheter administration, or one or more of the various well known routes of administration. In livestock, for example, the vaccine may be administered orally by incorporating the vaccine into feed or a liquid (e.g., water). It may be supplied as a lyophilized powder, as a frozen formulation, or as a component of a capsule, or as any other convenient pharmaceutically acceptable formulation that preserves the antigenicity of the vaccine. One of several well-known pharmaceutically acceptable diluents or excipients may be used in the vaccine of the present invention. Suitable diluents include, for example, sterile distilled water, physiological saline, phosphate buffer, etc. The amount of diluent may vary considerably, as will be recognized by those skilled in the art. Suitable excipients are also well-known to those skilled in the art and may be selected, for example, from A. Wade and PJ Weller, eds., Handbook of Pharmaceutical Excipients (1994) The Pharmaceutical Press: London. The dose administered may depend on the age, health condition, and weight of the individual; the type of individual; and, if any, the presence of concurrent treatments.
[0078] In some cases, the target Variantlisteria bacteria number between 100 and 10,000 bacteria (e.g., 100-7,500, 100-5,000, 100-4,000, 100-3,000, 100-2,500, 100-2,000, 100-1,500, 100-1,000, 500-10,000). 00, 500~7,500, 500~5,000, 500~4,000, 500~3,000, 500~2,500, 500~2,000, 500~1,500, 500~1,000, 1,000~10,000, 1,000~7,500, 1,000~5,000, 1,000~4,000, 1,000~3 ,000, 1,000~2,500, 1,000~2,000, 1,000~1,500, 1,500~10,000, 1,500~7,500, 1,500~5,000, 1,500~4,000, 1,500~3,000, 1,500~2,500, 1,500~2,000, 2,000~10,000 It is administered in doses ranging from 2,000 to 7,500, 2,000 to 5,000, 2,000 to 4,000, 2,000 to 3,000, 2,000 to 2,500, 2,500 to 10,000, 2,500 to 7,500, 2,500 to 5,000, 2,500 to 4,000, or 2,500 to 3,000 bacteria. In some cases, the dose is approximately 1,000 bacteria. In some cases, the dose is approximately 1,500 bacteria. In some cases, the dose is approximately 2,000 bacteria. In some cases, the dose is approximately 2,500 bacteria. In some cases, the dose is approximately 2,000 bacteria. In some cases, the dose is approximately 3,000 bacteria.
[0079] Vaccines may be used in dosage forms for oral administration, such as capsules, liquid solutions, suspensions, or elixirs, or in sterile liquids for formulations for parenteral, intranasal, intramuscular, or intravascular use, such as solutions or suspensions. According to the present invention, vaccines may be used in combination with pharmaceutically acceptable diluents as vaccine compositions useful for immunizing an individual against infection by a selected organism or virus, or with respect to tumors, etc. Immunizing an individual means providing the individual with at least some degree of therapeutic or prophylactic immunity against a selected pathogen, cancerous cells, etc.
[0080] Individuals can be any human or non-human animal susceptible to infection by the selected organism. The target vaccine is used in vertebrates such as mammals (including human and non-human mammals), and in particular in livestock. Livestock includes poultry, cattle, pigs, sheep, horses, goats, dogs, cats, rabbits (e.g., rabbits), or other non-human animals.
[0081] The vaccine in question is used in vertebrates in a manner to induce or boost a cellular immune response, such as a γ / δ T cell response, against selected factors, such as pathogenic organisms or tumors, and such a manner includes the step of administering an effective amount of the Listeria vaccine. The vaccine in question is used in a manner to induce an innate immune response in vertebrates that enhances an antigen-specific immune response. Furthermore, the vaccine of the present invention may be used for post-exposure or post-diagnosis treatment. Generally, the use of vaccines for post-exposure treatment will be recognized by those skilled in the art, for example, in the treatment of rabies and tetanus. The same vaccine of the present invention may be used, for example, both for post-exposure immunization and for boosting immunity. Alternatively, different vaccines of the present invention, such as those specific to antigens that manifest later in the exposure, may be used for post-exposure treatment. Thus, the vaccine in question is used as both a prophylactic and a therapeutic vaccine to induce an antigen-specific immune response associated with various disease conditions.
[0082] In certain embodiments of the method, the immunogenic composition of interest comprises a variant of Listeria bacterium genetically modified to contain one or more heterologous nucleic acids comprising a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, and the variant of Listeria bacterium grows aerobically. In some cases, the Listeria bacterium further comprises a loss-of-function mutation in the endogenous LytB gene. In such embodiments of the method, the immune response is induced to a phosphorylated antigen produced by the variant of Listeria bacterium. In some cases, the phosphorylated antigen is (E)-4-hydroxy-3-methyl-buta-2-enylpyrophosphate (HMBPP).
[0083] In certain embodiments of the method, the immunogenic composition of interest comprises a Variantlisteria bacterium genetically modified to contain a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous polypeptide. In such embodiments of the method, the immune response is induced against the heterologous polypeptide. In some cases, the heterologous polypeptide is an antigen as described herein. Suitable antigens include, but are not limited to, cancer-associated antigens and pathogen-associated antigens (e.g., viral antigens, pathogenic protozoan antigens, etc.). In some embodiments, the antigen is a cancer-associated antigen.
[0084] An additional aspect of the method involves administering an effective amount of an immunogenic composition containing a variant of Listeria bacterium of the Disclosure, including any combination of the above-described mutations / modifications, to an individual.
[0085] In certain aspects, the immune response includes a T cell response. In some cases, the immune response includes mucosa-associated invariant T (MAIT) cells, γ / δ T cells, and CD8 cells. + The immune response includes cytotoxic T cell and / or natural killer (NK) cell responses. In some embodiments, the immune response includes γ / δ T cell responses.
[0086] The vaccines in question are used for the vaccination applications described in PCT Publication Applications WO 2014 / 106123, WO 2014 / 074635, WO 2009 / 143085, WO 2008027560, WO 2008066774, WO 2007117371, WO 2007103225, WO 2005071088, WO 2003102168, WO 2003 / 092600, WO / 2000 / 009733, and WO 1999 / 025376. The disclosures of these applications are incorporated herein by reference.
[0087] The target bacterial strain (a Variantlisteria bacterium containing a mutation in the purA gene encoding adenylosuccinate synthase, and being an adenosine trophicer, is also used as an immunostimulant, i.e., an adjuvant. In such applications, the attenuated bacteria can be administered together with immunogens, such as tumor antigens or modified tumor cells, in accordance with methods known in the art in which live bacterial strains are used as adjuvants. See, for example, Berd et al., Vaccine 2001 Mar 21;19 (17-19):2565-70.
[0088] In some embodiments, bacterial strains are used as adjuvants by chemical coupling to sensitizing antigens. The sensitizing antigen may be any antigen of interest, and representative antigens of interest include, but are not limited to, viral factors, e.g., herpes simplex virus, malaria parasites; bacteria, e.g., Staphylococcus aureus, diphtheria toxoid, tetanus toxoid, schistosomiasis nymphae; tumor cells, e.g., CAD2 mammary gland adenocarcinoma tumor cells; and hormones, e.g., thyroxine T4, triiodothyronine T3, and cortisol. Coupling of sensitizing antigens to immunostimulants can be achieved by various chemical factors having two reaction sites, e.g., bisdiazobenzidine, glutaraldehyde, diiodoacetate, and diisocyanates, e.g., m-xylene diisocyanate and toluene-2,4-diisocyanate. The use of Listeria species as adjuvants is further described in U.S. Patent No. 4,816,253, which is incorporated herein by reference.
[0089] Examples of non-limiting aspects of this disclosure The aspects of the subject matter described above may be useful on their own or in combination with one or more other aspects or aspects. Without limiting the preceding description, certain non-limiting aspects of the present disclosure are provided below. As will be apparent to those skilled in the art after reading the present disclosure, each of the individual numbered aspects may be used or combined with any of the preceding or succeeding individual numbered aspects. This is intended to provide support for all such combinations of aspects, and is not limited to the combinations of aspects expressly shown below.
[0090] Phase 1. A bacterium of the genus Listeria containing a mutation in the purA gene encoding adenylosuccinate synthase, which is an adenosine nutrient requirement bacterium. Phase 2. The Variantlisteria bacterium described in Phase 1, which does not proliferate extracellularly in mammals. Phase 3. A variant of the genus *Platylisteria* from Phase 1 or Phase 2, wherein the mutation is a deletion of all or part of the purA gene. Phase 4. A variant of *Category 1* to 3* that requires 100 μM to 500 μM of adenosine supplementation for growth. Phase 5. A variant of the genus Listeria from any one of phases 1-4, further comprising a deletion of all or part of the endogenous ribC gene and / or the endogenous ribF gene. Phase 6. A variant of the genus Listeria that has been genetically modified to contain one or more heterologous nucleic acids, one of the variants described in Phases 1-5. Surface 7. A variant of the genus *Variantlisteria* from surface 6, wherein one or more of the heterologous nucleic acids are incorporated into the bacterial genome. Surface 8. The Variantlisteria bacterium of Surface 6 or 7, wherein one or more heterologous nucleic acids comprise a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, and the Variantlisteria bacterium grows aerobically. Scene 9. A variant of the genus Listeria according to Scene 8, wherein one or more heterologous nucleic acids contain nucleotide sequences encoding IspE, GcpE, and IspA polypeptides. Surface 10. A variant of the genus Listeria of Surface 8, wherein one or more heterologous nucleic acids contain nucleotide sequences encoding Dxs, IspD, IspF, IspE, GcpE, and IspA polypeptides. Phase 11. A variant of the genus Listeria from any one of phases 8-10, further containing a loss-of-function mutation in the endogenous LytB gene. Phase 12. A variant of the genus Listeria from any one of phases 8-11, further comprising one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions. Phase 13. Variantlisteria bacterium of Phase 12, wherein the one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions include mutations in endogenous genes selected from lmo1694, fur, flgE, ribF, uracil DNA glycosylase, DNA-directed RNA polymerase subunit α, UDP-N-acetylglucosamine 1-carboxyvinyltransferase, and heptaprenyl diphosphate synthase component I. Surface 14. A variant of the genus Listeria, any one of surfaces 6 to 13, wherein at least one of the one or more heterologous nucleic acids contains a nucleotide sequence encoding an antigen polypeptide. Phase 15. A variant of Listeria bacterium from Phase 14, wherein the antigen is a cancer-associated antigen. Phase 16. A bacterium of the genus Listeria, specifically one of the bacteria described in Phases 1-15, which is a Listeria monocytogenes bacterium. Phase 17. A Variantlisteria bacterium from any one of Phases 1 to 16, further comprising one or more additional mutations that give the bacterium a reduced phenotype and / or one or more additional mutations that provide a growth advantage. Phase 18. A variant of the genus Listeria of Phase 17, wherein the one or more additional mutations that give a weakened phenotype include mutations in genes selected from actA and inlB, and the one or more additional mutations that provide a growth advantage include mutations in the eetB gene. Phase 19. A composition comprising one of the Variantlisteria species bacteria from Phases 1 to 18. Surface 20. The composition of Surface 19, further comprising a multispecific antibody having (i) a first antigen-binding site specific to a cancer-associated antigen and (ii) a second antigen-binding site specific to T cells. Aspect 21. The T cells are mucosa-associated invariant T (MAIT) cells, γ / δ T cells, CD8 + A composition of surface 20, which consists of T cells or natural killer (NK) cells. Phase 22. An immunogenic composition containing one of the Variantlisteria species bacteria from Phases 1 to 18. Surface 23. A method for inducing an immune response in an individual, comprising the step of administering to the individual an effective amount of the immunogenic composition of Surface 22. Surface 24. The method of Surface 23, wherein the Variantlisteria bacterium is genetically modified to contain one or more heterologous nucleic acids comprising a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, the Variantlisteria bacterium grows aerobically, and the immune response is induced in response to a phosphorylated antigen produced by the Variantlisteria bacterium. Surface 25. The method of Surface 24, wherein the phosphorylated antigen is (E)-4-hydroxy-3-methyl-buta-2-enylpyrophosphate (HMBPP). Surface 26. The method of Surface 23, wherein the Variantlisteria bacterium is genetically modified to contain a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous polypeptide, and the immune response is induced against the heterologous polypeptide. Surface 27. The method of Surface 26, wherein the heterologous polypeptide is the antigen. Surface 28. The method of Surface 27, wherein the antigen is a cancer-associated antigen. Phase 29. Any one of the methods described in Phases 23-28, wherein the immune response includes a gamma-delta T cell response. A kit comprising a unit dose of the immunogenic composition of section 30, section 22. Surface 31. The kit of surface 30, wherein the unit dose is an oral dose. Surface 32. A kit of surface 30 in which the unit dose is injectable. Surface 33. One of the kits from surfaces 30-32, further comprising a recombinant expression vector containing a nucleotide sequence encoding a heterologous polypeptide. Surface 34. The kit of surface 33, wherein the heterologous polypeptide is the antigen. Surface 35. The kit of surface 34, wherein the antigen is a cancer-related antigen. [Examples]
[0091] The following examples are provided to those skilled in the art to provide a complete disclosure and explanation of how the present invention is prepared and used, and are not intended to limit the scope of what the inventors consider to be their invention, nor are they intended to represent all or only experiments that have been conducted. With regard to the numerical values used (e.g., quantity, temperature, etc.), efforts have been made to ensure accuracy, but some experimental error and deviation should be taken into consideration. Unless otherwise indicated, parts are by weight, molecular weight is weight-average molecular weight, temperature is in Celsius, and pressure is atmospheric pressure or near atmospheric pressure. For example, standard abbreviations such as bp, base pair; kb, kilobase; pl, picoliters; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acids; kb, kilobases; bp, base pair; nt, nucleotides; im, intramuscular; ip, intraperitoneal; sc, subcutaneous may be used.
[0092] Example 1 As a facultative intracellular pathogen, L. monocytogenes poses significant concerns regarding the safe administration of this bacterium in humans because it can also reproduce in the extracellular environment during systemic infection. The in vivo extracellular growth niches of L. monocytogenes include, but are not limited to, blood and gallbladder. Engineered strains that have lost the ability to reproduce in these niches would greatly improve the safe administration of L. monocytogenes. To achieve this, nutrients restricted in the extracellular environment were investigated, and it was found that the mean concentrations of purine bases and nucleosides in plasma and other extracellular fluids are low, generally in the range of 0.4–6 μM. More importantly, de novonucleotide biosynthesis was identified as the single most important metabolic function required for bacterial growth in human blood. Based on these findings, it was hypothesized that purine-requiring L. monocytogenes would not reproduce in the extracellular environment and therefore would greatly improve the safety profile of L. monocytogenes therapeutic agents.
[0093] We constructed a L. monocytogenes trophoblast for adenosine, a purine nucleoside that is limited in blood and healthy cells but abundant in the tumor microenvironment. The adenosine trophoblast was constructed by creating an in-frame deletion in the gene encoding adenylosuccinate synthase (purA), which is involved in the biosynthesis of adenyl species. This strain is hereafter referred to as ΔpurA. The ΔpurA mutant was adenosine-dependent, as it did not replicate in chemically defined media without adenosine supplementation (Figure 1). The minimum exogenous adenosine concentration required to support optimal proliferation of the trophoblast was 100 μM–500 μM (Figure 1), a concentration not typically present in the extracellular environment. Consistent with our hypothesis, the L. monocytogenes ΔpurA mutant did not proliferate under extracellular conditions, as demonstrated in defibrinized sheep blood and human serum (Figure 2).
[0094] Next, we examined the entry and proliferation of L. monocytogenes strains in host cells. In mouse bone marrow-derived macrophages (BMMs), the majority of ΔpurA mutants (70% compared to WT) escaped from phagosomes and entered the host cytoplasm (Figure 3A), but ΔpurA mutants in the cytoplasm failed to proliferate (Figure 3B). Restricted proliferation in the host cytoplasm may promote the induction of cell-mediated immunity (CMI) because the lower bacterial load per cell reduces the chance of APC cell death. Similar to observations in chemically defined media (Figure 1), replication of ΔpurA mutants in BMMs could only be restored when adenosine was supplemented at concentrations much higher than the physiologically relevant concentrations in vivo (Figure 3B).
[0095] Subsequently, the virulence and immunogenicity of the ΔpurA mutant during the in vivo infection period in mice were determined. Since ΔpurA proliferation was limited in the blood and cells, it was reasonable to observe significant attenuation of this strain during the systemic infection period in mice. The mutant showed a 2 log increase in bacterial load in the spleen compared to the wild type. 10 It shows a deficiency, and in the liver, 4 log 10The strain demonstrated attenuation (Figure 4A). We compared the ΔpurA strain with ΔactA, the major attenuating mutation found in live attenuated L. monocytogenes cancer vaccine strains that had been studied in previous preclinical and clinical trials. The two mutants behaved similarly in terms of CFU in the liver and spleen, but the ΔpurA strain was less detectable in the gallbladder, another in vivo extracellular proliferation niche of L. monocytogenes other than blood (Figure 4B). Although attenuated in mouse spleen, the ΔpurA mutant proliferated more than 10-fold in the first 24 hours after infection (Figure 4C), which may have contributed to the establishment of adaptive immunity. Therefore, we tested whether the strain of the present invention could induce robust CMI even at low doses, which may be desirable from a safety perspective. When the ΔpurA mutant was administered at a very low dose (1000 bacteria), it nearly completely protected mice from the second lethal dose challenge of WT L. monocytogenes, which was superior to the protection observed with the ΔactA strain (Figure 5A). Consistently, the ΔpurA mutant produced significantly more antigen-specific CD8 than the ΔactA mutant. + Cytotoxic T cells were induced (Figure 5B).
[0096] Another aspect of this strain is that the ΔpurA strain can survive within tumors due to its high adenosine concentration in the tumor microenvironment. The ΔpurA mutation can also be combined with other genetic / metabolic manipulations (e.g., actA / inlB and ribC / ribF deletions, suicide L. monocytogenes strains, or dead but metabolically active strains) to further improve the safety of therapeutic strains. The ΔpurA strain can be combined with multispecific antibodies that specifically direct T cells, including gamma-delta (γδ) T cells or mucosa-associated invariant T (MAIT) cells, to tumors.
[0097] References TIFF2026539107000007.tif233160TIFF2026539107000008.tif115159
[0098] While the present invention has been described with reference to its specific embodiments, those skilled in the art will understand that various modifications can be made and equivalents can be substituted without departing from the true spirit and scope of the invention. In addition, many modifications can be made to adapt specific situations, materials, compositions, processes, process steps, or steps to the purpose, spirit, and scope of the invention. All such modifications are intended to fall within the scope of the claims appended herein.
Claims
1. A bacterium of the genus Listeria containing a mutation in the purA gene encoding adenylosuccinate synthase, and which is an adenosine nutrient requirement bacterium.
2. The Variantlisteria bacterium according to claim 1, wherein the Variantlisteria does not proliferate extracellularly in mammals.
3. The variant of the genus Listeria according to claim 1 or 2, wherein the mutation is a deletion of all or part of the purA gene.
4. A bacterium of the genus Variantlisteria according to any one of claims 1 to 3, which requires adenosine supplementation of 100 μM to 500 μM for growth.
5. A variant of the genus Listeria according to any one of claims 1 to 4, further comprising the deletion of all or part of the endogenous ribC gene and / or the endogenous ribF gene.
6. A bacterium of the genus Variantlisteria according to any one of claims 1 to 5, which is genetically modified to contain one or more heterologous nucleic acids.
7. The Variantlisteria bacterium according to claim 6, wherein one or more heterologous nucleic acids are incorporated into the bacterial genome.
8. The Variantlisteria bacterium according to claim 6 or 7, wherein the one or more heterologous nucleic acids comprise a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, and the Variantlisteria bacterium grows aerobically.
9. The Variantlisteria bacterium according to claim 8, wherein the one or more heterologous nucleic acids include nucleotide sequences encoding IspE, GcpE, and IspA polypeptides.
10. The Variantlisteria bacterium according to claim 8, wherein the one or more heterologous nucleic acids include nucleotide sequences encoding Dxs, IspD, IspF, IspE, GcpE, and IspA polypeptides.
11. A variant of the genus Listeria according to any one of claims 8 to 10, further comprising a loss-of-function mutation in the endogenous LytB gene.
12. A variant of the genus Listeria according to any one of claims 8 to 11, further comprising one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions.
13. The Variantlisteria bacterium according to claim 12, wherein the one or more additional mutations that enhance the function of the non-mevalonate pathway under aerobic conditions include mutations in endogenous genes selected from lmo1694, fur, flgE, ribF, uracil DNA glycosylase, DNA-directed RNA polymerase subunit α, UDP-N-acetylglucosamine 1-carboxyvinyltransferase, and heptaprenyl diphosphate synthase component I.
14. A bacterium of the genus Variantlisteria according to any one of claims 6 to 13, wherein at least one of the one or more heterologous nucleic acids comprises a nucleotide sequence encoding an antigen polypeptide.
15. The bacterium of the genus Variantlisteria according to claim 14, wherein the antigen is a cancer-associated antigen.
16. A bacterium of the genus Listeria according to any one of claims 1 to 15, which is a bacterium of the genus Listeria, which is a bacterium of the genus Listeria monocytogenes.
17. The Variantlisteria bacterium according to any one of claims 1 to 16, further comprising one or more additional mutations that give the bacterium a reduced phenotype and / or one or more additional mutations that provide a growth advantage.
18. The variant of the genus Listeria according to claim 17, wherein the one or more additional mutations that give a weakened phenotype include mutations in genes selected from actA and inlB, and the one or more additional mutations that provide a growth advantage include mutations in the eetB gene.
19. A composition comprising a bacterium of the genus Variantlisteria as described in any one of claims 1 to 18.
20. The composition according to claim 19, further comprising a multispecific antibody having (i) a first antigen-binding site specific to a cancer-associated antigen and (ii) a second antigen-binding site specific to T cells.
21. The T cells include mucosa-associated invariant T (MAIT) cells, γ / δ T cells, CD8 + The composition according to claim 20, wherein the composition is a T cell or a natural killer (NK) cell.
22. An immunogenic composition comprising a bacterium of the genus Variantlisteria as described in any one of claims 1 to 18.
23. A method for inducing an immune response in an individual, comprising the step of administering to the individual an effective amount of the immunogenic composition according to claim 22.
24. The method according to claim 23, wherein the Variantlisteria bacterium is genetically modified to contain one or more heterologous nucleic acids comprising a nucleotide sequence encoding a polypeptide necessary for isoprenoid synthesis via a non-mevalonate pathway, the Variantlisteria bacterium grows aerobically, and the immune response is induced to a phosphorylated antigen produced by the Variantlisteria bacterium.
25. The method according to claim 24, wherein the phosphorylated antigen is (E)-4-hydroxy-3-methyl-buta-2-enylpyrophosphate (HMBPP).
26. The method according to claim 23, wherein the Variantlisteria bacterium is genetically modified to contain a heterologous nucleic acid comprising a nucleotide sequence encoding a heterologous polypeptide, and the immune response is induced against the heterologous polypeptide.
27. The method according to claim 26, wherein the heterologous polypeptide is an antigen.
28. The method according to claim 27, wherein the antigen is a cancer-related antigen.
29. The method according to any one of claims 23 to 28, wherein the immune response comprises a gamma-delta T cell response.
30. A kit comprising a unit dose of the immunogenic composition described in claim 22.
31. The kit according to claim 30, wherein the unit dose is an oral dose.
32. The kit according to claim 30, wherein the unit dose is injectable.
33. The kit according to any one of claims 30 to 32, further comprising a recombinant expression vector containing a nucleotide sequence encoding a heterologous polypeptide.
34. The kit according to claim 33, wherein the heterologous polypeptide is an antigen.
35. The kit according to claim 34, wherein the antigen is a cancer-related antigen.
